A Phase 1 interventional study of D-2570 in Renal Impairment, sponsored by InventisBio Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.
Among the 61 studies in Renal Insufficiency with a site in China, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 9 that started in 2026, is one of 22 in phase 1, reaches primary completion later than 5 of the 15 other live ones, and was the 59th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Sites in China
Ages 18–75
Taian Cancer Hospital · Sites in China
Ages 65+
Daihong Liu · Sites in China
Ages 14+
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC · Sites in China
Ages 16–85
Henan Genuine Biotech Co., Ltd. · Sites in China
Ages 18–70 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 3 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is close to the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 41 across the 48 interventional studies, 228 across the 13 observational. Of the 35 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 61 have an industry lead sponsor. The 10 most frequent:
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
InventisBio Co., Ltd has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Renal Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07715175InventisBio Co., LtdThe Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function. | 2026-11-21 |
| NCT06354231Fudan UniversityDV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | 2026-12-30 |
| NCT06351813Shanghai Zhongshan HospitalPredicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers | 2026-12-31 |
| NCT07938034CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function | 2027-07-15 |
| NCT07489534Daihong LiuStudy of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Renal Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is divided two parts into: Part A and Part B. Part A will recruit 24 research participants, and Part B will recruit 16 research participants.
Subjects of this study will be admitted to the Phase I ward of the research center one day before drug administration . On the first day, subjects will orally take a single dose of D-2570. The researchers will collect a series of blood and urine samples before and after drug D - 2570 administration to determine the drug concentration and evaluate the pharmacokinetic characteristics. The subjects can leave site after completing the safety evaluation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a single dose of D-2570
Drug: D-2570
Subjects will receive a single dose of D-2570 (Part B)
Drug: D-2570
Subjects will receive a single dose of D-2570 (Part A)
Drug: D-2570
Subjects will receive a single dose of D-2570 (Part A)
Drug: D-2570
receive a single dose of D-2570
The main PK parameters -Time to maximum measured plasma concentration -Tmax
The main PK parameters -Time to maximum measured plasma concentration -Tmax
Time frame: Through study completion (approximately Day9)
Maximum observed plasma concentration-Cmax
Maximum observed plasma concentration-Cmax
Time frame: Through study completion (approximately Day9)
The main PK parameters Half-life -t1/2
The main PK parameters Half-life -t1/2
Time frame: Through study completion (approximately Day9)
The main PK parameters#Area under the plasma concentration versus time curve-AUC
The main PK parameters#Area under the plasma concentration versus time curve-AUC
Time frame: Through study completion (approximately Day9)
The main PK parameters-CL/F (apparent clearance)
The main PK parameters-CL/F (apparent clearance)
Time frame: Through study completion (approximately Day9)
The main PK parameters-Vz/F (apparent volume of distribution)
The main PK parameters-Vz/F (apparent volume of distribution)
Time frame: Through study completion (approximately Day9)
The cumulative excretion amount (Aeu)
The cumulative excretion (Aeu) of D - 2570 and its metabolites in urine
Time frame: Through study completion (approximately Day9)
The fraction of drug excreted in urine (Feu)
The fraction of drug excreted in urine (Feu) of D - 2570 and its metabolites in urine
Time frame: Through study completion (approximately Day9)
The renal clearance rate (CLR)
The renal clearance rate (CLR)of D - 2570 and its metabolites in urine
Time frame: Through study completion (approximately Day9)
Number of participants with treatment-related adverse events as assessed by CTCAE v6.0
Incidence of adverse events
Time frame: Through study completion (approximately Day9)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2026, 3 months after the start.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 3 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570